公开(公告)号：EP0676398A3

公开(公告)日：1998-07-01

申请号：EP95302409

申请日：1995-04-11

申请人： SANKYO CO

发明人： FUJITA TAKASHI ,  FUJIMOTO KOICHI ,  YOSHIOKA TAKAO ,  YANAGISAWA HIROAKI ,  FUJIWARA TOSHIHIKO ,  HORIKOSHI HIROYOSHI ,  OGUCHI MINORU ,  WADA KUNIO

IPC分类号： C07D263/44 ,  A61K31/33 ,  A61K31/425 ,  A61P3/00 ,  A61P3/04 ,  A61P3/10 ,  A61P5/00 ,  C07D209/08 ,  C07D209/10 ,  C07D209/12 ,  C07D209/36 ,  C07D277/34 ,  C07D413/10 ,  C07D413/12 ,  C07D417/10 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  A61K31/49

CPC分类号： C07D413/12 ,  C07D209/08 ,  C07D209/10 ,  C07D209/12 ,  C07D209/36 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04

摘要： Compounds of formula (I): [wherein: X represents an unsubstituted or substituted indolyl, indolinyl, azaindolyl, azaindolinyl, imidazopyridyl or imidazopyrimidinyl group; Y represents an oxygen or sulphur atom; Z represents a 2,4-dioxothiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxooxazolidin-5-ylmethyl, 3,5-dioxooxadiazolidin-2-ylmethyl or
N -hydroxyureidomethyl group; R represents a hydrogen atom, an alkyl group, an alkoxy group, a halogen atom, a hydroxy group, a nitro group, an aralkyl group or a unsubstituted or substituted amino group; and
m is an integer of from 1 to 5] have hypoglycemic and anti-diabetic activities.

公开(公告)号：EP1239050A4

公开(公告)日：2004-07-21

申请号：EP00981649

申请日：2000-12-08

申请人： SANKYO CO

发明人： KOISHI RYUTA ,  ANDO YOSUKE ,  ONO MITSURU ,  FURUKAWA HIDEHIKO ,  HORIKOSHI HIROYOSHI ,  FUJIWARA TOSHIHIKO

IPC分类号： A61K38/00 ,  A61P3/06 ,  C07K16/18 ,  C07K16/22 ,  C12N15/12 ,  G01N33/50 ,  G01N33/68 ,  C12Q1/68 ,  A61K48/00 ,  C07K14/47 ,  C12N5/10 ,  C12Q1/02 ,  G01N33/563 ,  G01N33/92

CPC分类号： G01N33/5067 ,  A01K2267/0362 ,  C07K16/18 ,  C07K16/22 ,  C12N2799/022 ,  G01N33/50 ,  G01N33/5008 ,  G01N33/502 ,  G01N33/5023 ,  G01N33/6893 ,  G01N2500/20 ,  G01N2800/044

摘要： A novel method of testing a remedy or a preventive for hyperlipemia; and a nucleic acid probe, a primer and an antibody which are employed in this method. More particularly speaking, a method of testing the effect of a test substance as a remedy or a preventive for hyperlipemia by using the expression of a gene represented by SEQ ID NO:1 or 2 in Sequence Listing, which participates in the control of the blood neutral fat level of mammalians, as an indication; and a nucleic acid probe, a primer and an antibody employed in this method. By using this method, candidates for preventives or remedies for hyperlipemia can be searched for.

公开(公告)号：EP0953355A4

公开(公告)日：2002-02-27

申请号：EP97924253

申请日：1997-05-29

申请人： SANKYO CO

发明人： FUJIWARA TOSHIHIKO ,  KUARAKATA SHINICHI ,  FUJITA TAKASHI ,  HOSOKAWA TSUNEMICHI ,  FUKUSHIGE JUNICHIRO ,  HORIKOSHI HIROYOSHI

IPC分类号： A61K45/00 ,  C07D413/12 ,  C07D417/12 ,  A61K31/425 ,  A61K31/41 ,  A61K31/415

CPC分类号： C07D413/12 ,  C07D417/12

摘要： A preventive or remedy for autoimmune diseases excluding diabetes type I which contains as the active ingredient a substance improving insulin resistance.

公开(公告)号：EP0678511A3

公开(公告)日：1998-06-10

申请号：EP95301922

申请日：1995-03-23

申请人： SANKYO CO

发明人： FUJITA TAKASHI ,  YOSHIOKA TAKAO ,  YANAGISAWA HIROAKI ,  FUJIWARA TOSHIHIKO ,  HORIKOSHI HIROYOSHI ,  OGUCHI MINORU ,  WADA KUNIO ,  FUJIMOTO KOICHI

IPC分类号： A61K31/17 ,  A61K31/41 ,  C07D263/44 ,  C07D271/06 ,  C07D277/34 ,  C07D291/04 ,  C07D413/10 ,  C07D417/10 ,  C07D417/12 ,  C07D417/14 ,  C07D419/10 ,  C07D413/12 ,  C07D413/14 ,  C07D419/12 ,  C07D419/14

CPC分类号： C07D417/12 ,  C07D277/34 ,  C07D417/14

摘要： Compounds of formula (I): [in which: R and R are each hydrogen or alkyl, or together a group of formula -(CH2)k- in which k is an integer; R is hydrogen, alkyl, alkoxy, halogen or hydroxy; A and B are each hydrogen, alkyl, aralkyl, aliphatic carboxylic acyl, aryl-substituted aliphatic carboxylic acyl, aromatic carboxylic acyl or carbamoyl, or A and B together represent >C=O, >C=S, -C(=O)-C(=O)-, -CH2C(=O)-, -CH2CH2-, -SO2- or -CH2SO2-; X is a group of formula: W-(CH2)m-X - in which W is aryl or heterocyclic, X is a single bond, oxygen, sulphur or >NR in which R is hydrogen, alkyl, aralkyl or aryl, and m is 0 or an integer; Y is a group of formula: -(CH2)n-Y -, in which Y is a single bond, oxygen or sulphur, and n is an integer; Z is a group of formula (i), (ii), (iii), (iv), (v) or (vi): in which R is hydrogen, carboxyalkyl, alkanoyloxyalkyl, cycloalkyl-substituted alkanoyloxyalkyl, cycloalkylcarbonyloxyalkyl, alkoxycarbonyloxyalkyl, cycloalkyl-substituted alkoxycarbonyloxyalkyl or cycloalkyloxycarbonyloxyalkyl group]; and salts, esters and solvates thereof and pro-drugs therefor are useful for the treatment and/or prophylaxis of a variety of disorders, including one or more of: hyperlipemia, hyperglycemia, obesity, glucose tolerance insufficiency, insulin resistance and diabetic complications.